2C-H

Use and effects

There is no record of 2C-H trials in humans, as it would likely be destroyed by monoamine oxidase enzymes before causing any significant psychoactive effects. In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists both the dose and duration of 2C-H effects as unknown.

Pharmacology

Pharmacodynamics

2C-H acts as a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, albeit with far lower potency than other 2C drugs. It also shows affinity for the serotonin 5-HT1A receptor, higher than that of any other 2C drug. The drug exhibits agonist activity in vitro at the human trace amine associated receptor 1 (TAAR1).

2C-H produces visual and auditory changes in rodents, but is much less potent than other 2C drugs. It also produces hypolocomotion at high doses similarly to other psychedelics, but failed to affect prepulse inhibition in contrast to other psychedelics. The drug shows highly potent and fully efficacious anti-inflammatory effects.

Chemistry

Synthesis

The chemical synthesis of 2C-H has been described. It is used as a precursor in the synthesis of other phenethylamines such as 2C-B, 2C-I, and 2C-N.

Analogues and derivatives

2C-H (2,5-DMPEA) is one of several possible positional isomers of dimethoxyphenethylamine (DMPEA).

2C-H is the parent compound of the 2C series of psychedelic drugs, also known as 4-substituted 2,5-dimethoxyphenethylamines. These drugs include 2C-B, 2C-C, 2C-D, 2C-E, and 2C-I, among others.

The N-methyl derivative of 2C-H, N-methyl-2C-H, has reduced activational potency and efficacy at the serotonin 5-HT2A receptor compared to 2C-H.

History

2C-H was first synthesized in 1932 by Johannes S. Buck.

Society and culture

Legal status

Canada

As of October 31, 2016; 2C-H is a controlled substance (Schedule III) in Canada.

United States

As of July 9, 2012, 2C-H is a Schedule I controlled substance in the United States, under the Synthetic Drug Abuse Prevention Act of 2012. 2C-H's DEA Drug Code is 7517.

References

References

1. {{CitePiHKAL [https://www.erowid.org/library/books_online/pihkal/pihkal032.shtml 2C-H Entry in ''PiHKAL'']
2. (16 March 2025). "Kᵢ Database".
3. "BindingDB BDBM50026778 2-(2,5-Dimethoxy-phenyl)-ethylamine::2-(2,5-dimethoxyphenyl)ethylamine::CHEMBL287047".
4. (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology.
5. (2022). "Structure-activity Relation of Halogenated 2,5-Dimethoxyamphetamines Compared to their α‑Desmethyl (2C) Analogues". The FASEB Journal.
6. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Archives of Toxicology.
7. (April 2004). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes". British Journal of Pharmacology.
8. (June 2007). "Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors". The Journal of Pharmacology and Experimental Therapeutics.
9. (August 2000). "1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists". Journal of Medicinal Chemistry.
10. (December 1981). "Alpha-adrenergic agents. 1. Direct-acting alpha 1 agonists related to methoxamine". Journal of Medicinal Chemistry.
11. (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Testing and Analysis.
12. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". The Journal of Pharmacology and Experimental Therapeutics.
13. (August 2008). "Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1". Bioorganic & Medicinal Chemistry.
14. ""PubChem"".
15. (2022). "Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs". Frontiers in Psychiatry.
16. (November 2022). "Psychedelics as potent anti-inflammatory therapeutics". Neuropharmacology.
17. (2022). "Disruptive Psychopharmacology".
18. (April 2021). "Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore". ACS Pharmacology & Translational Science.
19. (2011). "[[The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds]]". [[Transform Press]].
20. (1932). "Hydroxy- and Dihydroxyphenylethylmethylamines and their Ether". Journal of the Chemical Society.
21. (4 May 2016). "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)".
22. "Rules - 2013 - Establishment of Drug Codes for 26 Substances (SDAPA)". U.S. Department of Justice.